SEHK:9926Biotechs
Akeso (SEHK:9926) Unveils Promising Data For IO-Resistant Lung Cancer Therapy
Akeso (SEHK:9926) recently captured attention by presenting promising data on its cadonilimab therapy at the World Conference on Lung Cancer, highlighting its potential as a breakthrough treatment for immunotherapy-resistant non-small cell lung cancer. Over the last quarter, the company's share price surged 40%, potentially influenced by these significant clinical developments and the awarding of Breakthrough Therapy Designation. The broader market trend, which saw indices like the S&P 500...
